ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

relmapirazin

Also written as “MB-102”, “Lumitrace” and “MB-102 and commercially available optical angiography imaging system”.

Its studies are mostly in Renal Insufficiency · Retinal Diseases · Blastic Plasmacytoid Dendritic Cell Neoplasm · Renal Insufficiency, Chronic · Acute Kidney Injury, led by 3 companies.

Drug pageRelmapirazin: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 21, 20228 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediBeaconits history only62 open or runningphase 3since Apr 21, 2022May 10, 2016Dec 2026phase 1 · NCT07080008
Huadong Medicineits history only10 open or runningphase 3since Mar 22, 2023Mar 22, 2023none ahead
Mustang Bio10 open or runningphase 2since Sep 25, 2019Sep 25, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mustang Bio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named relmapirazinINNProposed as its International Nonproprietary Name in WHO's List 117 · before, MB-102
  2. Sep 25, 2019First study: phase 2 study in Blastic Plasmacytoid Dendritic Cell NeoplasmFirst studyNCT04109482 · 3 enrolled · United States

TargetBeta

IL3RA →read by rule
“A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA) and ”NCIt, by rule

Other programs on IL3RA

ProgramCompanyFurthest phaseStudies
pivekimab sunirineruleAbbViephase 34

Studies

The one study Mustang Bio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04109482Blastic Plasmacytoid Dendritic Cell Neoplasm · United States2TerminatedMay 17, 20233

How it is read

Names in the registry

  • “MB-102”, 4 entries
  • “Lumitrace”, 1 entry
  • “MB-102 and commercially available optical angiography imaging system”, 1 entry
  • “MB-102 OMID”, 1 entry
  • “MB-102-- single dose of 4 µmol/kg”, 1 entry

Codes read as this program: MB102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.